148 related articles for article (PubMed ID: 36375679)
1. Censoring Time Trade-off Values at 0 Versus at -1: How Does the Assumption for Worse-Than-Dead Time Trade-off Values Affect the Modeling of EQ-5D-5L Valuation Data?
Yang Z; Rand K; Luo N
Value Health; 2023 May; 26(5):685-693. PubMed ID: 36375679
[TBL] [Abstract][Full Text] [Related]
2. Valuation of Health States Considered to Be Worse Than Death-An Analysis of Composite Time Trade-Off Data From 5 EQ-5D-5L Valuation Studies.
Gandhi M; Rand K; Luo N
Value Health; 2019 Mar; 22(3):370-376. PubMed ID: 30832976
[TBL] [Abstract][Full Text] [Related]
3. Censoring in the time trade-off valuation of worse-than-dead EQ-5D-5L health states: can a time-based willingness-to-accept question be the solution?
Liao M; Rand K; Yang Z; Hsu CN; Lin HW; Luo N
Qual Life Res; 2023 Apr; 32(4):1165-1174. PubMed ID: 36564637
[TBL] [Abstract][Full Text] [Related]
4. Valuation of the EQ-5D-5L with composite time trade-off for the German population - an exploratory study.
Ludwig K; von der Schulenburg JG; Greiner W
Health Qual Life Outcomes; 2017 Feb; 15(1):39. PubMed ID: 28219389
[TBL] [Abstract][Full Text] [Related]
5. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
[TBL] [Abstract][Full Text] [Related]
6. Does the Introduction of the Ranking Task in Valuation Studies Improve Data Quality and Reduce Inconsistencies? The Case of the EQ-5D-5L.
Ramos-Goñi JM; Rand-Hendriksen K; Pinto-Prades JL
Value Health; 2016 Jun; 19(4):478-86. PubMed ID: 27325340
[TBL] [Abstract][Full Text] [Related]
7. A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada.
Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA;
Med Care; 2016 Jan; 54(1):98-105. PubMed ID: 26492214
[TBL] [Abstract][Full Text] [Related]
8. Handling Data Quality Issues to Estimate the Spanish EQ-5D-5L Value Set Using a Hybrid Interval Regression Approach.
Ramos-Goñi JM; Craig BM; Oppe M; Ramallo-Fariña Y; Pinto-Prades JL; Luo N; Rivero-Arias O
Value Health; 2018 May; 21(5):596-604. PubMed ID: 29753358
[TBL] [Abstract][Full Text] [Related]
9. Comparison of online and face-to-face valuation of the EQ-5D-5L using composite time trade-off.
Jiang R; Shaw J; Mühlbacher A; Lee TA; Walton S; Kohlmann T; Norman R; Pickard AS
Qual Life Res; 2021 May; 30(5):1433-1444. PubMed ID: 33247810
[TBL] [Abstract][Full Text] [Related]
10. Beyond 10-year lead-times in EQ-5D-5L: leveraging alternative lead-times in willingness-to-accept questions to capture preferences for worse-than-dead states and their implication.
Chang JA; Hsu CN; Ramos-Goñi JM; Luo N; Lin HW; Lin FJ
Eur J Health Econ; 2023 Dec; ():. PubMed ID: 38072877
[TBL] [Abstract][Full Text] [Related]
11. How different are composite and traditional TTO valuations of severe EQ-5D-5L states?
Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA
Qual Life Res; 2016 Aug; 25(8):2101-8. PubMed ID: 26875190
[TBL] [Abstract][Full Text] [Related]
12. Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study: The Indian 5-Level Version EQ-5D Value Set.
Jyani G; Sharma A; Prinja S; Kar SS; Trivedi M; Patro BK; Goyal A; Purba FD; Finch AP; Rajsekar K; Raman S; Stolk E; Kaur M
Value Health; 2022 Jul; 25(7):1218-1226. PubMed ID: 35779943
[TBL] [Abstract][Full Text] [Related]
13. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe.
Golicki D; Jakubczyk M; Graczyk K; Niewada M
Pharmacoeconomics; 2019 Sep; 37(9):1165-1176. PubMed ID: 31161586
[TBL] [Abstract][Full Text] [Related]
14. Determinants of time trade-off valuations for EQ-5D-5L health states: data from the Canadian EQ-5D-5L valuation study.
Sayah FA; Bansback N; Bryan S; Ohinmaa A; Poissant L; Pullenayegum E; Xie F; Johnson JA
Qual Life Res; 2016 Jul; 25(7):1679-85. PubMed ID: 26659899
[TBL] [Abstract][Full Text] [Related]
15. Using the Choice Sequence in Time Trade-Off as Discrete Choices: Do the Two Stories Match?
Augestad LA; Rand K; Luo N; Barra M
Value Health; 2020 Apr; 23(4):487-494. PubMed ID: 32327166
[TBL] [Abstract][Full Text] [Related]
16. New methods for modelling EQ-5D-5L value sets: An application to English data.
Feng Y; Devlin NJ; Shah KK; Mulhern B; van Hout B
Health Econ; 2018 Jan; 27(1):23-38. PubMed ID: 28833854
[TBL] [Abstract][Full Text] [Related]
17. Preparatory study for the revaluation of the EQ-5D tariff: methodology report.
Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A
Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945
[TBL] [Abstract][Full Text] [Related]
18. Modeling ranking, time trade-off, and visual analog scale values for EQ-5D health states: a review and comparison of methods.
Craig BM; Busschbach JJ; Salomon JA
Med Care; 2009 Jun; 47(6):634-41. PubMed ID: 19433996
[TBL] [Abstract][Full Text] [Related]
19. Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L.
Hobbins A; Barry L; Kelleher D; Shah K; Devlin N; Goni JMR; O'Neill C
Pharmacoeconomics; 2018 Nov; 36(11):1345-1353. PubMed ID: 30051267
[TBL] [Abstract][Full Text] [Related]
20. Valuation of EQ-5D-5L health states: a comparison of seven Asian populations.
Wang P; Liu GG; Jo MW; Purba FD; Yang Z; Gandhi M; Pattanaphesaj J; Ahn J; Wong EL; Shafie AA; Busschbach JJ; Luo N
Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):445-451. PubMed ID: 30523723
[No Abstract] [Full Text] [Related]
[Next] [New Search]
